// App-Quantinova.ai

: Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Researchers

Presenter

  • John Timmerman

Principal Investigators

  • David Lavie

  • Nathalie A. Johnson

  • Abraham Avigdor

  • Peter Borchmann

  • Charalambos Andreadis

  • Ali Bazargan

  • Gareth P. Gregory

  • Colm Keane

  • Inna Tsoran-Rosenthal

  • Vladan Vucinic

  • Pier Luigi Zinzani

  • Rachel Marceau West

  • Pallavi Pillai

  • Akash Nahar

  • Alex F. Herrera

Medical Centers

  • IRCCS-University Hospital of Bologna Seragnoli Institute of Hematology and Department of Specialized, Diagnostic, and Experimental Medicine, University of Bologna, Bologna, Italy

  • UCSF, San Francisco, CA

  • Hadassah Medical Center, Jerusalem, Israel

  • Jewish General Hospital, Montreal, Canada

  • UCLA Medical Center, Los Angeles, CA

  • City of Hope, Duarte, CA

  • U. klinikum Koeln AOER, Cologne, Germany

  • Rambam Health Care Campus, Haifa, Israel

  • University of Melbourne, Melbourne, VIC, Australia; St Vincent's Hospital, Fitzroy, Australia

  • CHAIM SHEBA MEDICAL CENTER, Ramat Gan, Israel

  • School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

  • Princess Alexandra Hospital, Brisbane, Australia

  • Leipzig University Medical Center, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, Leipzig, Germany

Locations

  • Italy

  • Australia

  • Israel

  • United States

  • Germany

  • Canada

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Safety

  • Open Label

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved